Sector News

AstraZeneca CEO warns of medicine shortages after Brexit: Sunday Times

September 24, 2018
Life sciences

Britain could see widespread medicine shortages if there is no deal to prevent friction at the border with the European Union after Brexit, the AstraZeneca chief executive told the Sunday Times.

The company said in July it would stockpile drugs as a Brexit safety net, and CEO Pascal Soriot told the Sunday Times in an interview that the complexity of the supply chain in pharmaceuticals meant that delays would be likely.

“We have products that go back and forth between the UK and Europe at different stages of manufacturing,” he was quoted as saying. “If drugs are stuck, you have a problem.”

Separately, the Sunday Times reported that Jaguar Land Rover was considering following BMW’s lead and bringing forward its annual summer factory shutdown to coincide with Britain’s departure from the EU in case there is no deal, but added no decision had been taken.

By Alistair Smout

Source: Reuters

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).